Tateva Therapeutics Inc Profile last edited on: 5/6/20
CAGE: 813C6
UEI: EMMFE17E5K95
Business Identifier: NO Business Identifier is currently available for this company. 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 07
County: King
Congr. District: 07
County: King
Public Profile
Anchored in technology developed by the principal at - and licensed from - the University of Washington, Tateva Therapeutics researches and is developing novel therapeutics based on personalized molecular and cell therapies as well as biochemical analyses of different biologics.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2021 | 1 | NIH | $352,000 | |
| Project Title: Direct Reprogramming of Human Fibroblasts Into Functional Cardiomyocytes by Non-Integrating Cardiogenic Nanoparticles | ||||
Key People / Management
Anush Oganesian -- CEO
Company News
There are no news available.
